- Home
- UVSP vs XERS Comparison
UVSP vs XERS Comparison
Compare UVSP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UVSP | XERS |
|---|---|---|
| Founded | 1876 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 1.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UVSP | XERS |
|---|---|---|
| Price | $39.53 | $6.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $36.67 | $10.83 |
| AVG Volume (30 Days) | 139.0K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 21.32 | ★ 100.00 |
| EPS | ★ 0.96 | 0.01 |
| Revenue | ★ $328,056,000.00 | $49,590,000.00 |
| Revenue This Year | $11.65 | $34.37 |
| Revenue Next Year | $4.77 | $22.86 |
| P/E Ratio | ★ $40.93 | $633.00 |
| Revenue Growth | 9.64 | ★ 142.67 |
| 52 Week Low | $27.91 | $4.30 |
| 52 Week High | $40.17 | $10.08 |
Technical Indicators
Market Signals| Indicator | UVSP | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 48.72 |
| Support Level | $32.00 | $5.81 |
| Resistance Level | N/A | $6.41 |
| Average True Range (ATR) | 0.76 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 74.64 | 40.48 |
Price Performance
Historical ComparisonAbout UVSP Univest Financial Corporation
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.